Form 4: UTHR Director Raymond Dwek Awarded Stock Options

United Therapeutics Corp director Raymond Dwek was granted 3,650 stock options as part of an annual non-employee director award, exercisable from July 9, 2026.

Summary

• Raymond Dwek, a Director of United Therapeutics Corp (UTHR), was granted 3,650 stock options.
• The transaction date for this award is July 24, 2025.
• The stock options have an exercise price of $306.41 per share.
• These options will become exercisable on July 9, 2026, and will expire on July 24, 2035.
• The award is identified as an annual non-employee director award.
• The filing indicates this transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholder value creation, indicating a stable and routine corporate action.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• The transaction is part of a pre-planned Rule 10b5-1(c) plan, indicating a structured approach to insider transactions.

Future Outlook

This filing primarily details a future stock option grant to a director and does not provide a broader future outlook for the company's operations or financial performance.

Industry Context

The grant of stock options to non-employee directors is a standard compensation practice within the biotechnology and pharmaceutical industries, designed to attract and retain qualified board members and align their incentives with the company's long-term performance.

Comparison to Industry Standards

• The grant of stock options as part of non-employee director compensation is a common practice across the biotechnology and pharmaceutical industries, aligning director incentives with long-term shareholder value.
• Specific comparable companies would include other publicly traded biotech firms of similar market capitalization and stage of development, which routinely use equity awards for board members as a significant component of their compensation packages.

Related Party Transactions

• The stock option grant to a non-employee director is a form of related party transaction, though it is a standard and disclosed compensation practice for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The granted stock options will become exercisable on July 9, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine annual stock option grant to a non-employee director, which is a standard compensation practice and does not provide new information to alter an investment thesis or warrant a change in recommendation.

Keywords

United Therapeutics, UTHR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Award, Rule 10b5-1